SCHEMBL12953426

SCHEMBL12953426

CCOC(=O)COc1ccc(-c2ccccc2)cc1Oc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 2/20 0.52
▸ ALDH1A1 P00352 4/20 0.51
▸ KDM4E B2RXH2 4/20 0.51
▸ MAPT P10636 3/20 0.51
▸ HPGD P15428 3/20 0.51
▸ TP53 P04637 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ CYP1A2 P05177 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ CASP3 P42574 1/20 0.48
▸ CASP7 P55210 1/20 0.48
▸ CASP9 P55211 1/20 0.48
▸ PTPN1 P18031 2/20 0.46
▸ ABCB1 P08183 1/20 0.45
▸ PPARG P37231 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12953277 0.90 ESR1 (0.48) ESR1ALDH1A1KDM4EMAPTHPGD
SCHEMBL12952687 0.89 PPARD (0.48) ESR1ALDH1A1KDM4EMAPTHPGD
SCHEMBL13581124 0.85 PTGDR2 (0.52) ALDH1A1KDM4EMAPTHPGDCYP1A2
SCHEMBL12952678 0.84 ESR1 (0.46) ESR1ALDH1A1KDM4EMAPTHPGD
SCHEMBL12953279 0.82 ESR1 (0.43) ESR1ALDH1A1KDM4EMAPTHPGD
SCHEMBL12953044 0.81 PPARD (0.52) ESR1ALDH1A1KDM4EMAPTHPGD
SCHEMBL12953259 0.81 ESR1 (0.44) ESR1ALDH1A1KDM4EMAPTHPGD
SCHEMBL13580953 0.81 ESR1 (0.42) ESR1ALDH1A1KDM4EMAPTHPGD
SCHEMBL12953264 0.80 ALDH1A1 (0.46) ESR1ALDH1A1KDM4EMAPTHPGD
SCHEMBL12953282 0.80 ESR1 (0.46) ESR1ALDH1A1KDM4EMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633245-B2 PAI-1 inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2014-01-21 — — US disclosed
US-8633245-B2 PAI-1 inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2014-01-21 — — US disclosed
EP-2272817-A1 PAI-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2011-01-12 — — EP disclosed
US-20090312315-A1 PAI-1 INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-17 — — US disclosed
US-20090312315-A1 PAI-1 INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-17 — — US disclosed
WO-2009125606-A1 PAI-1 INHIBITOR 株式会社医薬分子設計研究所 (JP) 2009-10-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312315-A1 PAI-1 INHIBITOR SERPINC1, SERPINE1, SERPINH1 ESR1 1435/4885ALDH1A1 1168/4885KDM4E 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback